Thanks for your reply Michael. I so agree it has to change but haven’t a clue how to achieve it. I get angry when I think about NICE, who are interested only in the financial cost in, it appears, the short term. For example in the case of ixazomib, an oral drug, do they consider the monies saved in reduced hospital appointments.
All beyond me.
susie